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Abstract
Warfarin has long been considered the gold standard for stroke prevention in patients with
atrial fibrillation (AF). Recently, three major trials comparing the efficacy and safety of new
drugs: a thrombin inhibitor dabigatran and two inhibitors of factor Xa — rivaroxaban and
apixaban, with that of warfarin, have been published. The aim of this paper is to present the
main results of the RE-LY, ROCKET AF and ARISTOTLE trials, compare study populations
and outcomes, and discuss clinical implications of their results for the long-term anticoagula-
tion in patients with nonvalvular AF. (Cardiol J 2012; 19, 1: 4–10)
Key words: atrial fibrillation, stroke prevention, apixaban, dabigatran,
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Introduction
Atrial fibrillation (AF) is the commonest car-
diac arrhythmia. AF is a major risk factor for stroke
and systemic embolism. It causes an almost five-
-fold independent increase in the risk of ischemic
stroke and is responsible for at least 20% of all
strokes [1, 2]. AF-related strokes are associated
with a high recurrence rate and worst survival [3].
The use of vitamin K antagonists (VKA) is the most
effective standard therapy to prevent stroke and
systemic events in patients with AF and is more
beneficial than antiplatelet agents [4, 5]. VKA, first
introduced about 60 years ago, were until recently
the only available oral anticoagulants, and are re-
commended as the gold standard therapy by clinical
guidelines [6]. Warfarin, the most commonly used
VKA, reduces the risk of stroke by approximately
60% in patients with nonvalvular AF [5]. There are,
however, several limitations to warfarin treatment.
Warfarin therapy requires regular measurement of
the international normalized ratio (INR). An INR
value of 2.0–3.0 is the therapeutic range for stroke
prevention [7]. Data from clinical trials show that
patients with AF achieve the therapeutic INR range
only during 60% of treatment time [8]. Multiple
drug and food interactions, inter-individual and day-
-to-day variations in dose response require frequent
laboratory monitoring and dose adjustment.
Importantly, treatment with warfarin significant-
ly increases the risk of hemorrhage; about 2% of
patients per year experience major bleeding [9]. The
risk of bleeding is especially important in patients
with AF after acute coronary syndromes and/or per-
cutaneous interventions during triple anticoagulant
therapy. High treatment inertion of warfarin (delayed
onset of action, long half-life) often requires heparin
bridging therapy before different interventional pro-
cedures, and increases the risk of bleeding during
urgent surgical operations. Probably because of these
limitations, only 54% of patients with indications for
oral anticoagulants are actually treated with VKA;
older patients (age > 80 years) and individuals with
paroxysmal AF are especially undertreated [10].
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As a consequence of limitations related to war-
farin treatment, attempts have been made to pro-
duce oral anticoagulant drugs targeting specific
components of the coagulation cascade.
The process of coagulation is a complex pro-
teinase cascade, comprising more than 30 differ-
ent proteins. Both the intrinsic and extrinsic path-
ways of coagulation lead to the formation of throm-
bin (factor IIa) though the activation of factor X —
the central element of the common coagulation
pathway [11].
Of the many possible targets for the new drugs
in the coagulation pathway, thrombin and factor Xa
inhibitors have been tested. So far, large phase III
clinical trials for the prevention of stroke in patients
with AF have been completed for dabigatran, riva-
roxaban and apixaban.
Among these new drugs, dabigatran, a specific
thrombin inhibitor, has been already included in the
US guidelines on the management of AF [12].
Dabigatran etexilate is a prodrug converted into the
active principle dabigatran by blood esterases. Its
metabolism is independent of the P450 cytochrome,
and so far only a few drug interactions have been
identified (amiodarone, varapamil, macrolides and
tenophovir), with no known food interactions. It is
eliminated mostly with urine, which makes the ad-
justment of dosage in patients with renal insufficien-
cy necessary [13].
Rivaroxaban is a new oral direct factor Xa in-
hibitor, which has been recently approved in Eu-
rope for the treatment of AF. It has a rapid onset
of action, with a half-life of 5–12 hours. Most of the
drug is eliminated by the kidneys: one third in the
unchanged, active form, and two thirds after be-
ing metabolized by the liver. The metabolites are
also partly eliminated with feces. The only known
interactions of rivaroxaban are with antimycotic
azole drugs and protease inhibitors used in HIV
therapy [14].
Apixaban, another oral direct Xa inhibitor, has
a half-life of 9–14 hours, with elimination pathways
that include metabolism and renal excretion. It is
eliminated mostly by the liver [15].
Recently, three pivotal trials addressing the ef-
ficacy and safety of new oral anticoagulants in pa-
tients with non-valvular AF have been published.
In RE-LY [16], two different doses of dabigatran
were used, while ROCKET AF [17] and ARISTO-
TLE [18] studied rivaroxaban and apixaban, respec-
tively.
The aim of this paper is to present the main
results of ARISTOTLE, RE-LY and ROCKET AF,
compare study populations and outcomes, and dis-
cuss clinical implications of their results for the
long-term anticoagulation in patients with nonval-
vular AF.
Characteristics and results of the studies
ARISTOTLE [18] was a double-blind, double-
-dummy, event-driven, phase III trial of stroke or
systemic embolism prevention in patients with non-
-valvular AF; 18,201 patients were randomized to
either a Xa inhibitor apixaban at a dose of 5 mg bid
(2.5 mg bid with ≥ 2 of the following criteria: age
≥ 80 years, body weight £ 60 kg, or serum creati-
nine level ≥ 1.5 mg/dL), or dose-adjusted warfarin
to a target INR of 2.0 to 3.0.
Patients had nonvalvular AF and ≥ 1 risk fac-
tors for stroke: previous stroke, transient ischemic
attack (TIA) or systemic embolism, age ≥ 75 years,
heart failure or left ventricular ejection fraction
(LVEF) £ 40%, diabetes mellitus, or hypertension.
The mean CHADS2 score [19] was 2.1; 19% of the
patients had a previous stroke, systemic embolism
or TIA. The primary efficacy end-point (stroke or
systemic embolism) occurred in 212 patients in the
apixaban arm (1.27%/year) and in 265 patients in
the warfarin arm (1.6%/year). Apixaban not only
proved to be non-inferior (HR 0.79; 95% CI 0.66–
–0.95; p < 0.001 for noninferiority), but also supe-
rior to warfarin (p = 0.01 for superiority) in the in-
tention-to-treat (ITT) population. The primary safe-
ty end-point — major bleeding — occurred in
327 patients in the apixaban arm (2.13%/year) and
in 462 patients in the warfarin arm (3.09%/year);
HR 0.69; 95% CI 0.60–0.80; p < 0.001. Intracranial
bleeding, other location bleeding, major or clinical-
ly relevant non-major bleeding and any bleeding
were more common in the warfarin arm (warfarin
vs apixaban 0.80%/year vs 0.33%/year, 2.27%/year
vs 1.79%/year, 6.01%/year vs 4.07%/year and
25.8%/year vs 18.1%/year, respectively). The inci-
dence of death from any cause was significantly low-
er in the apixaban arm (apixaban vs warfarin 3.52%/
/year vs 3.94%//year; HR 0.89; 95% CI 0.80–0.99;
p = 0.047). Thus, ARISTOTLE showed that apixa-
ban administration in patients with non-valvular AF
and mean CHADS2 score of 2.1 was superior to
warfarin in the prevention of stroke or systemic
embolism, and resulted in less bleeding and lower
mortality.
RE-LY [16] was a randomized, phase III trial
of stroke or systemic embolism prevention, per-
formed also in patients with non-valvular AF; 18,113
patients were randomized to receive, in a blinded
fashion, fixed doses of a IIa inhibitor dabigatran —
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either 110 mg or 150 mg bid — or, in an unblinded
fashion, dose-adjusted warfarin to an INR of 2.0–3.0.
Patients had AF and ≥ 1 of the following features:
history of stroke or TIA, LVEF < 40%, NYHA class
≥ II, age ≥ 75 or age 65–74 plus diabetes mellitus,
hypertension or coronary artery disease. The mean
CHADS2 score was 2.1. History of previous stroke
or TIA was present in 20.1% of patients. The pri-
mary efficacy end-point was the same as in ARIS-
TOTLE (stroke or systemic embolism), and — af-
ter correction for additional events identified after
publication of the primary paper [20] — occurred
in 183 patients in the dabigatran 110 mg bid arm
(1.54%/year), in 134 patients in the dabigatran
150 mg bid arm (1.11%/year), and in 202 patients
in the warfarin arm (1.71%/year). Dabigatran at both
doses was noninferior to warfarin (RR 0.90; 95% CI
0.74–1.10; p < 0.001 for noninferiority and RR 0.65;
95% CI 0.52–0.81; p < 0.001 for noninferiority, re-
spectively) in the ITT population. The 150 mg bid
dose of dabigatran was also superior to warfarin (RR
0.65; 95% CI 0.52–0.81; p < 0.001 for superiority).
The primary safety end-point — major hemorrhage
— occurred in 342 patients in the dabigatran 110 mg
bid arm (2.87%/year), in 399 patients in the dabiga-
tran 150 mg bid arm (3.32%/year), and in 421 pa-
tients in the warfarin arm (3.57%/year); RR 0.80;
95% CI 0.70–0.93; p = 0.003 and RR 0.93; 95%
CI 0.81–1.07; p = 0.31, respectively. Major gastro-
intestinal (GI) bleedings were most common in the
dabigatran 150 mg bid arm (dabigatran 150 mg
bid vs warfarin 1.56%/year vs 1.08%/year). Life-
-threatening bleeding, intracranial bleeding, minor
bleeding and major or minor bleeding occurred less
frequently in the dabigatran arms (dabigatran
110 mg bid and 150 mg bid vs warfarin: 1.24%/year
and 1.49%/year vs 1.80%/year; 0.23%/year and
0.30%/year vs 0.74%/year; 13.16%/year and
14.84%/year vs 16.37%/year; 14.62%/year and
16.42%/year vs 18.15%/year, respectively).
In summary, in RE-LY, dabigatran at a dose of
110 mg bid was noninferior to warfarin in the pre-
vention of stroke or systemic embolism, causing
less major bleeding. Dabigatran 150 mg bid, in the
same population, was superior to warfarin in the
prevention of stroke or systemic embolism, with no
difference in the risk of major bleeding.
ROCKET AF [17] was a double-blind, double-
-dummy, event-driven, phase III trial of stroke or
systemic embolism prevention in patients with non-
-valvular AF. The study randomized 14,264 patients
to receive either rivaroxaban at a dose of 20 mg od
(15 mg od in patients with creatinine clearance 30–
–49 mL/min) or dose-adjusted warfarin to a target
INR of 2.5 (range 2.0–3.0 inclusive). In order to be
included in the study, the patients had to have AF
and a positive history for stroke, TIA or systemic
embolism, or ≥ 2 additional risk factors for stroke:
heart failure or LVEF £ 35%, hypertension, age
≥ 75, and diabetes mellitus. The mean CHADS2
score was 3.5. A majority of the patients (54.8%)
had a previous stroke, systemic embolism or TIA.
The primary efficacy end-point (stroke or syste-
mic embolism) occurred in 188 patients in the riva-
roxaban arm (1.7%/year) and in 241 patients in the
warfarin arm (2.2%/year). Rivaroxaban proved to be
noninferior to warfarin (HR 0.79; 95% CI 0.66–0.96;
p < 0.001 for noninferiority) in the per protocol, as
treated population. In the safety as treated popu-
lation, the primary efficacy end-point occurred in
189 patients in the rivaroxaban arm (1.7%/year) and
in 243 patients in the warfarin arm (2.2%/year); HR
0.79; 95% CI 0.65–0.95; p = 0.02 for superiority. In
the ITT population, the primary efficacy end-point
occurred in 269 patients in the rivaroxaban arm
(2.1%/year) and in 306 patients in the warfarin arm
(2.4%.year); HR 0.88; 95% CI 0.75–1.03;
p < 0.001 for noninferiority; p = 0.12 for superio-
rity. The principal safety end-point, a composite of
major and non-major clinically relevant bleeding
events, occurred in 1,475 patients in the rivaroxa-
ban arm (14.9%/year) and in 1,449 patients in the
warfarin arm (14.5%/year); HR 1.03; 95% CI 0.96–
–1.11; p = 0.44. Transfusion, decrease of hemoglo-
bin ≥ 2.0 g/dL and major bleeding from gastrointes-
tinal site occurred less frequently in the warfarin
arm (warfarin vs rivaroxaban 1.3%/year vs 1.6%/
/year, 2.3%/year vs 2.8%/year and 2.2% vs 3.2%,
respectively). Critical bleeding, fatal bleeding and
intracranial hemorrhage were more common in the
warfarin arm (warfarin vs rivaroxaban 1.2%/year vs
0.8%/year, 0.5%/year vs 0.2%/year and 0.7%/year
vs 0.5%/year, respectively). In general, ROCKET
AF showed that rivaroxaban was non-inferior to
warfarin in the prevention of stroke or systemic em-
bolism, with no difference in the risk of major and
non-major clinically relevant bleeding. It is note-
worthy that intracranial and fatal bleeding occurred
less frequently in the rivaroxaban arm.
Comparison of the studies and outcomes
A comparison of the main characteristics of the
three studies is presented in Table 1. The studies
differed in a number of important respects.
ARISTOTLE and ROCKET AF were blinded
in both arms, while in RE-LY warfarin therapy was
open label.
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In ROCKET AF, CHADS2 score was higher
than in the two other studies. This resulted in
a higher all-cause mortality in the warfarin arm
(4.95% per year in ROCKET AF vs 3.94 in ARIS-
TOTLE and 4.13 in RE-LY), and also in a higher inci-
dence of primary end-point events (2.4, 1.6 and
1.69% per year, respectively).
Also data analysis was not identical. In ARIS-
TOTLE and RE-LY, primary analyses were carried
out in the ITT population, while in ROCKET AF it
was done in the per-protocol as treated and safety
as treated cohorts; ITT data was, however, provided.
It is noteworthy that in ARISTOTLE data acqui-
sition terminated when about 70% of subjects were
still on the study drug, while in ROCKET AF all pa-
tients at that time had been switched over to warfarin.
Primary efficacy outcomes in the three studies
are shown in Figure 1. All three drugs proved non-
inferior compared to warfarin. There was a general
trend in favor of study drugs, but the level of signif-
icance for superiority was only reached for apixaban,
dabigatran 150 mg bid in the ITT and rivaroxaban
in the as treated, but not in the ITT, analysis.
Figure 2 illustrates other efficacy and safety
outcomes in the three trials. It is interesting that,
except dabigatran at the dose of 150 mg bid, no
study drug offered better ischemic stroke preven-
tion than warfarin (Fig. 2A).
On the safety side, all three new drugs signifi-
cantly reduced the incidence of hemorrhagic stroke
and intracranial hemorrhage (Figs. 2B, E). This rep-
resents a clear advantage of apixaban, dabigatran and
rivaroxaban over warfarin. Apparently, reduction in
the number of hemorrhagic rather than ischemic
strokes accounted for the superiority of the new
drugs in some analyses, as described above. Inter-
estingly, none of the trials directly reported the num-
ber of peripheral embolic events, the other primary
outcome component. The RE-LY study was published
first, and brought up a concern about a statistically
marginal increase in the incidence of myocardial in-
farction with dabigatran (Fig. 2D). ARISTOTLE and
ROCKET AF did not confirm this observation. Al-
though all-cause mortality was significantly reduced
in ARISTOTLE only, a similar trend was also obser-
ved in the two other studies (Fig. 2F).
Table 1. Comparison of main characteristics, end-points and definitions in the ARISTOTLE, RE-LY and
ROCKET AF studies.
ARISTOTLE [18] RE-LY [16] ROCKET AF [17]
Study drug Apixaban Dabigatran Rivaroxaban
Comparator Warfarin (INR 2–3)
N 18,201 18,113 14,264
Study design Double-blind Open-label (warfarin) Double-blind
non-inferiority non-inferiority non-inferiority
Dose of study drug 5 mg bid 110 mg bid 20 mg od
2.5 mg bid for patients or 150 mg bid 15 mg od for moderate
with ≥ 2 at baseline: (randomized to two renal impairment
age ≥ 80 years; separate arms) (CrCl 30–49 mL/min)
weight £ 60 kg;
serum creatinine
≥ 1.5 mg/dL
Primary efficacy Stroke and systemic
end-point embolism
Principal safety                                              Major bleeding Composite of major
end-point and non-major clinically
relevant bleeding
Definition of major Clinically overt Bleeding associated Clinically overt bleeding
bleeding bleeding with: with: associated with:
• ØHb ≥ 2 g/dL • ØHb ≥ 2 g/dL • ØHb ≥ 2 g/dL
• Transfusion of • Transfusion of • Transfusion of ≥ 2 U
≥ 2 U of RBC ≥ 2 U of blood of RBC/whole blood
• Fatal bleeding • Symptomatic bleeding • Fatal bleeding
• Critical site bleeding in a critical area or organ • Critical anatomic
site bleeding
• Permanent disability
Mean CHADS2 score 2.1 2.1 3.5
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Figure 2. Other efficacy and safety outcomes in ARISTOTLE, RE-LY and ROCKET AF; Api — apixaban; Dab 110 —
dabigatran 110 mg bid; Dab 150 — dabigatran 150 mg bid; Riv — rivaroxaban; HR — hazard ratio; CI – confidence
interval; ITT — intention to treat; SAT — safety as treated; p — level of significance for superiority. Data from:
Connolly et al. [16]; Patel et al. [17]; Granger et al. [18].
Figure 1. Primary efficacy end-point in ARISTOTLE, RE-LY and ROCKET AF; HR — hazard ratio; CI — confidence
interval; ITT — intention to treat; p — level of significance for superiority.
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Clinical implications
Despite important differences, the general
message from the three trials is consistent. Com-
pared to warfarin, the three drugs have a potential
to reduce stroke and systemic embolism, with simi-
lar or improved safety.
No need for laboratory control and no need for
drug dose adjustment, as well as no food and very
few drug interactions, are the major advantages of
the novel oral anticoagulant drugs.
However, while the necessity to accurately
monitor the INR with warfarin may be considered
a disadvantage, it also gives the physician a possi-
bility to control the drug compliance and hemostatic
parameters of the patient. This is not possible with
the new generation of anticoagulants, as no speci-
fic laboratory tests are known to monitor the levels
of anticoagulation during their use. For rivaroxaban,
a concentration-dependent prolongation of pro-
thrombin time (PT), dilute PT, and activated par-
tial thromboplastin time was observed; however,
the results varied depending on the reagents and
could not be standardized [21].
A secondary analysis of the RE-LY trial data
showed that for all vascular events, non-hemorrha-
gic events and mortality, the advantages of dabiga-
tran were greater at sites with poor than at those
with good INR control, showing that the benefit of
new treatments may depend on the local standards
of care [22].
The efficacy and safety of the new drugs may
differ for different subgroups. The beneficial effect
of dabigatran is better expressed in patients aged
< 75 years [23]. Special attention should be paid to
patients with impaired renal function. In ARIS-
TOTLE and ROCKET AF, the doses of apixaban
and rivaroxaban were adjusted in patients with im-
paired glomerular filtration rate. The problem, how-
ever, is even more important with dabigatran. Re-
cently, a concern has been expressed about an in-
creased threat of bleeding and the need for initial,
and thereafter systematic, renal function monitor-
ing in patients receiving dabigatran [24].
A major disadvantage of the new drugs in cas-
es of serious bleeding or where there is a need for
emergency surgical intervention is the lack of spe-
cific antidotes to immediately correct the coagula-
tion. This disadvantage may be soon overcome, at
least in the case of the Xa inhibitors. Recently,
Eerenberg et al. [25] evaluated the potential of pro-
thrombin complex concentrate (PCC) to reverse the
anticoagulant effect of rivaroxaban and dabigatran
in healthy subjects. They found that PCC immedi-
ately and completely reverses the anticoagulant
effect of rivaroxaban, but not that of dabigatran.
This example may reflect general differences
between the IIa and Xa blockade [26].
Blockade of the Xa factor results in inhibition
of new thrombin production, with no effect on the
already existing thrombin. In addition, the physio-
logical role of factor Xa is restricted to its action in
both coagulation pathways, although it may also
have a proinflammatory effect. Thrombin, on the
other hand, apart from clot formation and inflam-
matory response, also plays a role as a mitogenic
factor and coagulation promoter. Cessation of IIa fa-
ctor blockade may result in a rebound thrombin
overproduction. Therefore, factor Xa inhibition
might be theoretically safer than thrombin block-
ade. It has to be emphasized, however, that direct
comparisons of the two drug classes are lacking.
Finally, economic aspects have to be taken into
consideration. Understandably, the direct costs of
warfarin treatment are much lower than that of the
new drugs. Initial data do however suggest that the
new treatments may still be cost-effective [27].
Conclusions
Apixaban, rivaroxaban and dabigatran repre-
sent attractive alternatives to standard warfarin
treatment in patients with nonvalvular AF. Their
administration does not require regular laboratory
monitoring. They are not only non-inferior to war-
farin, but in many respects, including intracranial
bleeds and hemorrhagic strokes, show superiority.
Direct between-trial, and thus between-drug, com-
parison is difficult and requires further evaluation.
The cost effectiveness of the new therapies needs
further studies.
The introduction of the specific Xa and IIa in-
hibitors represents a major step forward in the
treatment of patients with AF. Nonetheless, in pa-
tients with well controlled, stable INR values, war-
farin may remain a valid treatment option.
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